ClinicalTrials.gov record
Completed Phase 3 Interventional

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

ClinicalTrials.gov ID: NCT03036488

Public ClinicalTrials.gov record NCT03036488. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 13, 2026, 6:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)

Study identification

NCT ID
NCT03036488
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Enrollment
1,174 participants

Conditions and interventions

Interventions

  • Carboplatin Drug
  • Cyclophosphamide Drug
  • Doxorubicin Drug
  • Epirubicin Drug
  • Granulocyte colony stimulating factor: Filgrastim or Pegfilgastrim Biological
  • Paclitaxel Drug
  • Pembrolizumab Biological
  • Placebo Drug

Drug · Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 6, 2017
Primary completion
Oct 13, 2025
Completion
Oct 13, 2025
Last update posted
Oct 28, 2025

2017 – 2025

United States locations

U.S. sites
47
U.S. states
22
U.S. cities
41
Facility City State ZIP Site status
Virginia G. Piper Cancer Center Pharmacy - Scottsdale Healthcare ( Site 0089) Scottsdale Arizona 85268
Arizona Oncology Associates PC- HOPE ( Site 8001) Tucson Arizona 85711
Cedars Sinai Medical Center ( Site 0091) Los Angeles California 90048
Pacific Cancer Care ( Site 0069) Monterey California 93940
ICRI ( Site 0072) Whittier California 90603
University of Colorado Cancer Center ( Site 0021) Aurora Colorado 80045
Yale University School of Medicine ( Site 0054) New Haven Connecticut 06510
Christiana Hospital ( Site 0029) Newark Delaware 19713
Univ of Miami-Sylvester Comprehensive Cancer Center- Kendall satellite ( Site 0079) Miami Florida 33176
The University of Chicago Medical Center ( Site 0047) Chicago Illinois 60637-1447
North Shore University Health System ( Site 0081) Evanston Illinois 60201
Orchard Healthcare Research Inc. ( Site 0049) Skokie Illinois 60077
Goshen Center for Cancer Care ( Site 0010) Goshen Indiana 46526
University of Iowa Hospital and Clinics ( Site 0038) Iowa City Iowa 52242
New England Cancer Specialists ( Site 0005) Scarborough Maine 04074
Henry Ford Hospital ( Site 0003) Detroit Michigan 48202
Minnesota Oncology Hematology, PA ( Site 8013) Minneapolis Minnesota 55404
Rutgers Cancer Institute of New Jersey ( Site 0073) New Brunswick New Jersey 08903
Broome Oncology, LLC ( Site 8002) Johnson City New York 13790
Nyack Hospital Infusion Center ( Site 0059) Nyack New York 10960
TriHealth Cancer Institute-Good Samaritan Hospital ( Site 0044) Cincinnati Ohio 45220
Oncology Hematology Care, Inc. ( Site 8011) Cincinnati Ohio 45242
Providence Portland Medical Center ( Site 0052) Portland Oregon 97213
Northwest Cancer Specialists, P.C. ( Site 8008) Portland Oregon 97227
Magee - Women's Hospital ( Site 0011) Pittsburgh Pennsylvania 15213
Rhode Island Hospital ( Site 0060) Providence Rhode Island 02903
The West Clinic, P.C. ( Site 0078) Germantown Tennessee 38138
Texas Oncology-Austin Central ( Site 8005) Austin Texas 78731
Parkland Health and Hospital System ( Site 0093) Dallas Texas 75235
Texas Oncology-Baylor Charles A. Sammons Cancer Center ( Site 8006) Dallas Texas 75246
Simmons Cancer Center ( Site 0094) Dallas Texas 75390-9015
UT Southwestern Medical Center ( Site 0030) Dallas Texas 75390-9179
Moncrief Cancer Institute ( Site 0092) Fort Worth Texas 76104
Texas Oncology-Memorial City ( Site 8003) Houston Texas 77024
Houston Methodist Cancer Center ( Site 0013) Houston Texas 77030
Texas Oncology- Plano East ( Site 8010) Plano Texas 75075
Texas Oncology-San Antonio Northeast ( Site 8012) San Antonio Texas 78217
Texas Oncology-Tyler ( Site 8007) Tyler Texas 75702
University of Virginia ( Site 0022) Charlottesville Virginia 22903
Virginia Cancer Specialists, PC ( Site 8009) Fairfax Virginia 22031
Bon Secours Cancer Institute Medical Oncology at St. Mary's ( Site 0033) Midlothian Virginia 23114
Peninsula Cancer Institute, LLC ( Site 0041) Newport News Virginia 23601
Virginia Oncology Associates ( Site 8000) Norfolk Virginia 23502
Kadlec Clinic Hematology and Oncology ( Site 0087) Kennewick Washington 99336
Seattle Cancer Care Alliance ( Site 0068) Seattle Washington 98109
Medical Oncology Associates (Summit Cancer Centers) ( Site 0014) Spokane Washington 99208
YVMH dba Vrigina Mason Memorial/North Star Lodge Cancer Center ( Site 8004) Yakima Washington 98902

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 146 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03036488, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Oct 28, 2025 · Synced May 13, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03036488 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →